The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease

Expert Opinion on Drug Discovery

Volumn 11, Issue 7, 2016, Pages 733-744

  Cazzola, Mario ^a   Calzetta, Luigino ^a   Rogliani, Paola ^a   Matera, Maria Gabriella ^b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Clinical trials; COPD; PDE4; phenotype; roflumilast

Indexed keywords

ROFLUMILAST; AMINOPYRIDINE DERIVATIVE; BENZAMIDE DERIVATIVE; CYCLOPROPANE DERIVATIVE; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR;

ARTICLE; ASTHMA; CHRONIC BRONCHITIS; CHRONIC COUGH; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMBINATION DRUG THERAPY; DISEASE EXACERBATION; DRUG APPROVAL; DRUG SCREENING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LUNG FUNCTION; NONHUMAN; PRECLINICAL STUDY; PRIORITY JOURNAL; RISK REDUCTION; SPUTUM; ANIMAL; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; METABOLISM; METHODOLOGY; PATHOPHYSIOLOGY; PHENOTYPE; PROCEDURES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

AMINOPYRIDINES; ANIMALS; BENZAMIDES; CLINICAL TRIALS AS TOPIC; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; CYCLOPROPANES; HUMANS; PHENOTYPE; PHOSPHODIESTERASE 4 INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESEARCH DESIGN;

EID: 84969612679     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1080/17460441.2016.1184642     Document Type: Article

References (103)

1. K.F.Chung Phosphodiesterase inhibitors in airways disease. Eur J Pharmacol. 2006 8;533:110–117. doi:10.1016/j.ejphar.2005.12.059
2. A.Castro, M.J.Jerez, C.Gil, et al. Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: advances in the development of specific phosphodiesterase inhibitors. Med Res Rev. 2005;25:229–244. doi:10.1002/(ISSN)1098-1128.
3. D.H.Maurice, H.Ke, F.Ahmad, et al. Advances in targeting cyclic nucleotide phosphodiesterases. Nat Rev Drug Discov. 2014;13:290–314. doi:10.1038/nrd4228.
4. C.P.Page, D.Spina. Phosphodiesterase inhibitors in the treatment of inflammatory diseases. Handb Exp Pharmacol. 2011;204:391–414. doi:10.1007/978-3-642-17969-3_17.
5. D.Spina, L.J.Landells, C.P.Page. The role of phosphodiesterase enzymes in allergy and asthma. Adv Pharmacol. 1998;44:33–89.
6. M.D.Houslay. Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown. Trends Biochem Sci. 2010;35:91–100. doi:10.1016/j.tibs.2009.09.007.
7. M.D.Houslay, D.R.Adams. PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem J. 2003;370:1–18. doi:10.1042/BJ20021698.
8. C.K.Billington, I.R.Le Jeune, K.W.Young, et al. A major functional role for phosphodiesterase 4D5 in human airway smooth muscle cells. Am J Respir Cell Mol Biol. 2008;38:1–7. doi:10.1165/rcmb.2007-0171OC.
9. C.Schudt, H.Tenor, A.Hatzelmann. PDE isoenzymes as targets for anti-asthma drugs. Eur Respir J. 1995;8:1179–1183.
10. S.L.Jin, S.Goya, S.Nakae, et al. Phosphodiesterase 4B is essential for TH2-cell function and development of airway hyperresponsiveness in allergic asthma. J Allergy Clin Immunol. 2010;126:1252–9.e12. doi:10.1016/j.jaci.2010.08.014.
11. M.G.Matera, C.Page, M.Cazzola. PDE inhibitors currently in early clinical trials for the treatment of asthma. Expert Opin Investig Drugs. 2014;23:1267–1275. doi:10.1517/13543784.2014.921157.• An interesting review in which the authors describe the main PDE families that could be involved in asthma as well as the PDE inhibitors that have been evaluated for the treatment of asthma.
12. M.G.Matera, P.Rogliani, L.Calzetta, et al. Phosphodiesterase inhibitors for chronic obstructive pulmonary disease: what does the future hold? Drugs. 2014;74:1983–1992. doi:10.1007/s40265-014-0303-8.
13. R.Barber, G.S.Baillie, R.Bergmann, et al. Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers. Am J Physiol Lung Cell Mol Physiol. 2004;287:L332–43. doi:10.1152/ajplung.00384.2003.
14. L.Gobejishvili, D.V.Avila, D.F.Barker, et al. S-adenosylmethionine decreases lipopolysaccharide-induced phosphodiesterase 4B2 and attenuates tumor necrosis factor expression via cAMP/protein kinase A pathway. J Pharmacol Exp Ther. 2011;337:433–443. doi:10.1124/jpet.110.174268.
15. C.P.Page, D.Spina. Selective PDE inhibitors as novel treatments for respiratory diseases. Curr Opin Pharmacol. 2012;12:275–286. doi:10.1016/j.coph.2012.02.016.
16. W.M.Brown. Cilomilast GlaxoSmithKline. Curr Opin Investig Drugs. 2005;6:545–558.
17. ® (apremilast) approved by the European Commission for the treatment of both patients with psoriasis and psoriatic arthritis [cited 2016 Mar18]. Available from: http://ir.celgene.com/releasedetail.cfm?releaseid=891728.
18. P.H.Schafer, A.Parton, A.K.Gandhi, et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol. 2010;159:842–855. doi:10.1111/j.1476-5381.2009.00559.x.
19. H.Amschler Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors. PCT Patent WO95/01338;1995.
20. A.Hatzelmann, C.Schudt. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther. 2001;297:267–279.
21. M.A.Giembycz, S.K.Field. Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD. Drug Des Devel Ther. 2010;4:147–158.
22. N.G.Knebel, R.Herzog, F.Reutter, et al. Sensitive quantification of roflumilast and roflumilast N-oxide in human plasma by LC-MS/MS employing parallel chromatography and electrospray ionisation. J Chromatogr B Analyt Technol Biomed Life Sci. 2012;893-894:82–91. doi:10.1016/j.jchromb.2012.02.038.
23. G.Lahu, A.Hünnemeyer, E.Diletti, et al. Population pharmacokinetic modelling of roflumilast and roflumilast N-oxide by total phosphodiesterase-4 inhibitory activity and development of a population pharmacodynamic-adverse event model. Clin Pharmacokinet. 2010;49:589–606. doi:10.2165/11536600-000000000-00000.
24. A.Hatzelmann, E.J.Morcillo, G.Lungarella, et al. The preclinical pharmacology of roflumilast–a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2010;23:235–256. doi:10.1016/j.pupt.2010.03.011.
25. F.Mori, S.Pérez-Torres, R.De Caro, et al. The human area postrema and other nuclei related to the emetic reflex express cAMP phosphodiesterases 4B and 4D. J Chem Neuroanat. 2010;40:36–42. doi:10.1016/j.jchemneu.2010.03.004.
26. D.S.Bundschuh, M.Eltze, J.Barsig, et al. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp Ther. 2001;297:280–290.
27. N.A.Jones, V.Boswell-Smith, R.Lever, et al. The effect of selective phosphodiesterase isoenzyme inhibition on neutrophil function in vitro. Pulm Pharmacol Ther. 2005;18:93–101. doi:10.1016/j.pupt.2004.10.001.
28. M.Mata, B.Sarria, A.Buenestado, et al. Phosphodiesterase 4 inhibition decreases MUC5AC expression induced by epidermal growth factor in human airway epithelial cells. Thorax. 2005;60:144–152. doi:10.1136/thx.2004.025692.
29. A.Buenestado, S.Grassin-Delyle, F.Guitard, et al. Roflumilast inhibits the release of chemokines and TNF-α from human lung macrophages stimulated with lipopolysaccharide. Br J Pharmacol. 2012;165:1877–1890. doi:10.1111/j.1476-5381.2011.01667.x.
30. H.J.Kwak, J.S.Song, J.Y.Heo, et al. Roflumilast inhibits lipopolysaccharide-induced inflammatory mediators via suppression of nuclear factor-κB, p38 mitogen-activated protein kinase, and c-Jun NH2-terminal kinase activation. J Pharmacol Exp Ther. 2005;315:1188–1195. doi:10.1124/jpet.105.092056.
31. A.Buenestado, M.C.Chaumais, S.Grassin-Delyle, et al. Roflumilast inhibits lipopolysaccharide-induced tumor necrosis factor-α and chemokine production by human lung parenchyma. PLoS One. 2013;8:e74640. doi:10.1371/journal.pone.0074640.
32. T.Victoni, T.Gicquel, A.Bodin, et al. Roflumilast n-oxide associated with PGE2 prevents the neutrophil elastase-induced production of chemokines by epithelial cells. Int Immunopharmacol. 2015;30:1–8. doi:10.1016/j.intimp.2015.11.019.
33. T.Victoni, F.Gleonnec, M.Lanzetti, et al. Roflumilast N-oxide prevents cytokine secretion induced by cigarette smoke combined with LPS through JAK/STAT and ERK1/2 inhibition in airway epithelial cells. PLoS One. 2014;9:e85243. doi:10.1371/journal.pone.0085243.
34. J.Milara, M.Armengot, P.Bañuls, et al. Roflumilast N-oxide, a PDE4 inhibitor, improves cilia motility and ciliated human bronchial epithelial cells compromised by cigarette smoke in vitro. Br J Pharmacol. 2012;166:2243–2262. doi:10.1111/j.1476-5381.2012.01929.x.
35. A.Schmid, N.Baumlin, P.Ivonnet, et al. Roflumilast partially reverses smoke-induced mucociliary dysfunction. Respir Res. 2015;16:135. doi:10.1186/s12931-015-0294-3.
36. P.A.Martorana, R.Beume, M.Lucattelli, et al. Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke. Am J Respir Crit Care Med. 2005;172:848–853. doi:10.1164/rccm.200411-1549OC.
37. P.A.Martorana, B.Lunghi, M.Lucattelli, et al. Effect of roflumilast on inflammatory cells in the lungs of cigarette smoke-exposed mice. BMC Pulm Med. 2008;8:17. doi:10.1186/1471-2466-8-17.
38. M.Fitzgerald, D.Spicer, A.E.Mcaulay, et al. Roflumilast but not methylprednisolone inhibited cigarette smoke-induced pulmonary inflammation in guinea pigs [abstract]. Eur Respir J Suppl. 2006;663s:P3850.
39. K.McCluskie, U.Klein, C.Linnevers, et al. Phosphodiesterase type 4 inhibitors cause proinflammatory effects in vivo. J Pharmacol Exp Ther. 2006;319:468–476. doi:10.1124/jpet.106.105080.
40. S.Susuki-Miyata, M.Miyata, B.C.Lee, et al. Cross-talk between PKA-Cβ and p65 mediates synergistic induction of PDE4B by roflumilast and NTHi. Proc Natl Acad Sci U S A. 2015;112:E1800–9. doi:10.1073/pnas.1418716112.
41. M.J.Sanz, J.Cortijo, M.A.Taha, et al. Roflumilast inhibits leukocyte-endothelial cell interactions, expression of adhesion molecules and microvascular permeability. Br J Pharmacol. 2007;152:481–492. doi:10.1038/sj.bjp.0707428.
42. B.J.Lipworth. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet. 2005;365:167–175. doi:10.1016/S0140-6736(05)17708-3.
43. D.C.Grootendorst, S.A.Gauw, R.M.Verhoosel, et al. The PDE4 inhibitor roflumilast reduces sputum neutrophil and eosinophil numbers in patients with COPD. Thorax. 2007;62:1081–1087. doi:10.1136/thx.2006.075937.
44. K.F.Rabe, E.D.Bateman, D.O’Donnell, et al. Roflumilast – an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2005;366:563–571. doi:10.1016/S0140-6736(05)67100-0.
45. P.M.Calverley, F.Sanchez-Toril, A.McIvor, et al. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;176:154–161. doi:10.1164/rccm.200610-1563OC.
46. K.F.Rabe. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br J Pharmacol. 2011;163:53–67. doi:10.1111/j.1476-5381.2011.01218.x.
47. K.P.Garnock-Jones. Roflumilast: a review in COPD. Drugs. 2015;75:1645–1656. doi:10.1007/s40265-015-0463-1.
48. S.I.Rennard, P.M.Calverley, U.M.Goehring, et al. Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD. Respir Res. 2011;12:18. doi:10.1186/1465-9921-12-122.
49. P.M.Calverley, K.F.Rabe, U.M.Goehring, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet. 2009;374:685–694.•• The pivotal trials that documented that roflumilast improves lung function and reduces the frequency of exacerbations in patients with bronchitic symptoms and severe airflow limitation.
50. J.A.Wedzicha, K.F.Rabe, F.J.Martinez, et al. Efficacy of roflumilast in the COPD frequent exacerbator phenotype. Chest. 2013;143:1302–1311. doi:10.1378/chest.12-1489.•• A pooled analysis of data from two 1-year, placebo-controlled, roflumilast studies in patients with symptomatic COPD and severe airflow obstruction documenting that treatment with roflumilast shifts patients from the frequent to the more stable infrequent exacerbator state.
51. L.M.Fabbri, P.M.Calverley, J.L.Izquierdo-Alonso, et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with long-acting bronchodilators: two randomised clinical trials. Lancet. 2009;374:695–703. doi:10.1016/S0140-6736(09)61252-6.
52. L.Pan, Y.Z.Guo, B.Zhang, et al. Does roflumilast improve dyspnea in patients with chronic obstructive pulmonary disease? A meta-analysis. J Thorac Dis. 2013;5:422–429. doi:10.3978/j.issn.2072-1439.2013.08.26.
53. M.Cazzola, W.MacNee, F.J.Martinez, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J. 2008;31:416–469. doi:10.1183/09031936.00099306.
54. D.E.O’Donnell, D.Bredenbröker, M.Brose, et al. Physiological effects of roflumilast at rest and during exercise in COPD. Eur Respir J. 2012;39:1104–1112. doi:10.1183/09031936.00096511.
55. S.D.Lee, D.S.Hui, A.A.Mahayiddin, et al. Roflumilast in Asian patients with COPD: a randomized placebo-controlled trial. Respirology. 2011;16:1249–1257. doi:10.1111/j.1440-1843.2011.02038.x.
56. J.Zheng, J.Yang, X.Zhou, et al. Roflumilast for the treatment of COPD in an Asian population: a randomized, double-blind, parallel-group study. Chest. 2014;145:44–52. doi:10.1378/chest.13-1252.
57. J.Chong, B.Leung, P.Poole. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013;11:CD002309.
58. Y.Oba, N.A.Lone. Efficacy and safety of roflumilast in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Ther Adv Respir Dis. 2013;7:13–24. doi:10.1177/1753465812466167.
59. J.H.Yan, W.J.Gu, L.Pan. Efficacy and safety of roflumilast in patients with stable chronic obstructive pulmonary disease: a meta-analysis. Pulm Pharmacol Ther. 2014;27:83–89. doi:10.1016/j.pupt.2013.04.004.
60. J.Luo, K.Wang, D.Liu, et al. Can roflumilast, a phosphodiesterase-4 inhibitor, improve clinical outcomes in patients with moderate-to-severe chronic obstructive pulmonary disease? A meta-analysis. Respir Res. 2016;17:18. doi:10.1186/s12931-016-0330-y.
61. A.B.Taegtmeyer, J.D.Leuppi, G.A.Kullak-Ublick. Roflumilast – a phosphodiesterase-4 inhibitor licensed for add-on therapy in severe COPD. Swiss Med Wkly. 2012;142:w13628.
62. B.Beghè, K.F.Rabe, L.M.Fabbri. Phosphodiesterase-4 inhibitor therapy for lung diseases. Am J Respir Crit Care Med. 2013;188:271–278. doi:10.1164/rccm.201301-0021PP.
63. W.B.White, G.E.Cooke, P.R.Kowey, et al. Cardiovascular safety in patients receiving roflumilast for the treatment of COPD. Chest. 2013;144:758–765. doi:10.1378/chest.12-2332.
64. European Medicines Agency. Daxas – Roflumilast [cited 2015 Dec20]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/001179/WC500089626.pdf.
65. FDA. US Food and Drug Administration FDA approves new drug to treat chronic obstructive pulmonary disease [cited 2015 Dec20]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncemen ts/ucm244989. htm.
66. Y.Wan, S.X.Sun, S.Corman, et al. A longitudinal, retrospective cohort study on the impact of roflumilast on exacerbations and economic burden among chronic obstructive pulmonary disease patients in the real world. Int J Chron Obstruct Pulmon Dis. 2015;10:2127–2136. doi:10.2147/COPD.S80106.
67. A.Z.Fu, S.X.Sun, X.Huang, et al. Lower 30-day readmission rates with roflumilast treatment among patients hospitalized for chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2015;10:909–915. doi:10.2147/COPD.S83082.
68. E.Worndl, E.B.Hunt, M.P.Kennedy, et al. Roflumilast in COPD. Chest. 2015;148:e31. doi:10.1378/chest.15-0664.
69. T.Yu, K.Fain, C.M.Boyd, et al. Benefits and harms of roflumilast in moderate to severe COPD. Thorax. 2014;69:616–622. doi:10.1136/thoraxjnl-2013-203884.
70. M.A.Puhan, T.Yu, C.M.Boyd, et al. Quantitative benefit-harm assessment for setting research priorities: the example of roflumilast for patients with COPD. BMC Med. 2015;13:157. doi:10.1186/s12916-015-0398-0.
71. W.De Backer, W.Vos, C.Van Holsbeke, et al. The effect of roflumilast in addition to BA/LAMA/ICS treatment in COPD patients. Eur Respir J. 2014;44:527–529. doi:10.1183/09031936.00011714.
72. F.J.Martinez, P.M.Calverley, U.M.Goehring, et al. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet. 2015;385:857–866. doi:10.1016/S0140-6736(14)62410-7.•• An important study suggesting that roflumilast reduces exacerbations and hospital admissions in patients with severe COPD and chronic bronchitis who are at risk of frequent and severe exacerbations despite ICS and LABA therapy, even in combination with tiotropium.
73. M.Muñoz-Esquerre, M.Diez-Ferrer, C.Montón, et al. Roflumilast added to triple therapy in patients with severe COPD: a real life study. Pulm Pharmacol Ther. 2015;30:16–21. doi:10.1016/j.pupt.2014.10.002.
74. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of COPD [Updated 2016; cited 2016 Mar17]. Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report%202016.pdf.
75. M.Cazzola, P.Rogliani, L.Novelli, et al. Inhaled corticosteroids for chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2013;14:2489–2499. doi:10.1517/14656566.2013.848856.
76. E.F.M.Wouters, D.S.Postma, B.Fokkens, et al. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax. 2005;60:480–487. doi:10.1136/thx.2004.034280.
77. N.A.Hanania, P.M.Calverley, M.T.Dransfield, et al. Pooled subpopulation analyses of the effects of roflumilast on exacerbations and lung function in COPD. Respir Med. 2014;108:366–375. doi:10.1016/j.rmed.2013.09.018.• A pooled analysis of two 52-week randomized, placebo-controlled, double-blind studies, showing that the addition of roflumilast to LABA therapy for 1 year in patients who discontinued ICS prior to study entry significantly reduced the risk of COPD exacerbations and improved lung function.
78. G.Lahu, A.Facius. Application of population pharmacokinetic modeling to explore the impact of alternative roflumilast dosing regimens on tolerability. Int J Clin Pharmacol Ther. 2013;51:832–836.
79. H.Hwang, J.Y.Shin, K.R.Park, et al. Effect of a dose-escalation regimen for improving adherence to roflumilast in patients with chronic obstructive pulmonary disease. Tuberc Respir Dis (Seoul). 2015;78(4):321–325. doi:10.4046/trd.2015.78.4.321
80. Y.Samyshkin, M.Schlunegger, S.Haefliger, et al. Cost-effectiveness of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland. Int J Chron Obstruct Pulmon Dis. 2013;8:79–87. doi:10.2147/COPD.S37486.
81. K.Moll, S.X.Sun, J.J.Ellis, et al. Impact of roflumilast on exacerbations of COPD, health care utilization, and costs in a predominantly elderly Medicare Advantage population. Int J Chron Obstruct Pulmon Dis. 2015 Mar;16(10):565–576.
82. Y.Samyshkin, R.W.Kotchie, A.C.Mörk, et al. Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom. Eur J Health Econ. 2014;15:69–82. doi:10.1007/s10198-013-0456-5.
83. E.D.Bateman, P.M.O’Byrne, R.Buhl, et al. Roflumilast for asthma: weighing the evidence. Pulm Pharmacol Ther. 2015;35(Suppl):S1–3. doi:10.1016/j.pupt.2015.08.001.
84. P.J.Barnes. Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2013;131:636–645. doi:10.1016/j.jaci.2012.12.1564.
85. M.Cazzola, S.Picciolo, M.G.Matera. Roflumilast in chronic obstructive pulmonary disease: evidence from large trials. Expert Opin Pharmacother. 2010;11(3):441–449. doi:10.1517/14656560903555201.
86. Committee for proprietary medicinal products (CPMP). Points to consider on clinical investigation of medicinal products in the chronic treatment of patients with chronic obstructive pulmonary disease (COPD) [cited 2015 Dec 21]. Available from: http://www.emea.europa.eu/pdfs/human/ewp/056298en.pdf.
87. E.P.Walker Panel votes against new PDE4 inhibitor for COPD [updated 2010; [cited 2015 Dec21]. Available from: http://www.medpagetoday.com/Pulmonology/SmokingCOPD/19448.
88. M.Cazzola. The divergent opinions of regulatory authorities on roflumilast are puzzling but we need new drugs for treating chronic obstructive pulmonary disease. Ther Adv Respir Dis. 2010;4:195–198. doi:10.1177/1753465810377636.
89. G.J.Criner, J.Bourbeau, R.L.Diekemper, et al. Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. Chest. 2015;147:894–942. doi:10.1378/chest.14-1676.•• Useful article on the prevention of acute exacerbations of COPD.
90. H.Kankaanranta, T.Harju, M.Kilpeläinen, et al. Diagnosis and pharmacotherapy of stable chronic obstructive pulmonary disease: the Finnish guidelines. Basic Clin Pharmacol Toxicol. 2015;116:291–307. doi:10.1111/bcpt.12366.
91. M.Miravitlles, J.J.Soler-Cataluña, M.Calle, et al. Guía Española de la EPOC (GesEPOC). Tratamiento farmacológico de la EPOC estable. Aten Primaria. 2012;44:425–437. doi:10.1016/j.aprim.2012.04.005.
92. G.Bettoncelli, F.Blasi, V.Brusasco, et al. The clinical and integrated management of COPD. An official document of AIMAR (Interdisciplinary Association for Research in Lung Disease), AIPO (Italian Association of Hospital Pulmonologists), SIMER (Italian Society of Respiratory Medicine), SIMG (Italian Society of General Medicine). Multidiscip Respir Med. 2014;9:25.
93. V.Koblizek, J.Chlumsky, V.Zindr, et al. Chronic Obstructive Pulmonary Disease: official diagnosis and treatment guidelines of the Czech Pneumological and Phthisiological Society; a novel phenotypic approach to COPD with patient-oriented care. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2013;157:189–201. doi:10.5507/bp.2013.039.
94. M.Cazzola, P.Rogliani, M.G.Matera. Escalation and de-escalation of therapy in COPD: myths, realities and perspectives. Drugs. 2015;75:1575–1585. doi:10.1007/s40265-015-0450-6.
95. J.Milara, J.Lluch, P.Almudever, et al. Roflumilast N-oxide reverses corticosteroid resistance in neutrophils from patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2014;134:314–322. doi:10.1016/j.jaci.2014.02.001.
96. A.Segreti, E.Stirpe, P.Rogliani, et al. Defining phenotypes in COPD: an aid to personalized healthcare. Mol Diagn Ther. 2014;18:381–388. doi:10.1007/s40291-014-0100-9.
97. D.P.Tashkin. Roflumilast: the new orally active, selective phophodiesterase-4 inhibitor, for the treatment of COPD. Expert Opin Pharmacother. 2014;15:85–96. doi:10.1517/14656566.2013.837159.
98. B.L.Barker, C.E.Brightling. Phenotyping the heterogeneity of chronic obstructive pulmonary disease. Clin Sci (Lond). 2013;124:371–387. doi:10.1042/CS20120340.
99. S.Suissa, K.F.Rabe. Point: were industry-sponsored roflumilast trials appropriate? yes. Chest. 2014;145:937–939. doi:10.1378/chest.14-0112.
100. J.Rho, N.Ho, V.Prasad. Counterpoint: were industry-sponsored roflumilast trials appropriate? no. Chest. 2014;145:939–942. doi:10.1378/chest.14-0114.
101. E.Sapey, R.A.Stockley. COPD exacerbations. 2: aetiology. Thorax. 2006;61:250–258. doi:10.1136/thx.2005.041822.
102. M.Bafadhel, S.McKenna, S.Terry, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit gCare Med. 2011;184:662–671. doi:10.1164/rccm.201104-0597OC.
103. J.M.Wells, P.L.Jackson, L.Viera, et al. A randomized, placebo-controlled trial of roflumilast effect on proline-glycine-proline and neutrophilic inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;192:934–942. doi:10.1164/rccm.201503-0543OC.